Abstract
The prophylactic effect of low doses of human leukocyte interferon (HuIFN-a) against infection with rhinovirus was measured in double-blind, placebo-controlled studies with volunteer subjects. An antihistamine (chlorpheniramine) was given before administration of single or multiple doses of HuIFN-a by saturated cotton pledget or by aerosol; volunteers were then challenged with rhinovirus. When the results for all groups were combined, a lower frequency of respiratory illness was demonstrated in the HuIFNa-treated volunteers (20 of 39 vs. 11 of 38, P <0.05). A significant improvement in mean symptom scores was found only in the volunteers who received HuIFN-a by cotton pledget. The total numbers of isolates of rhinovirus and seroconversions were similar for HuIFN-a-treated and control volunteers. No significant side effects were noted in the HuIFN-a-treated volunteers. Higher concentrations or improved methods of delivery of HuIFN-a will be necessary for improving the clinical efficacy of HuIFN-a against viral infections in the respiratory system.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 542-546 |
| Number of pages | 5 |
| Journal | Journal of Infectious Diseases |
| Volume | 145 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1982 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus. / Greenberg, S. B.; Harmon, M. W.; Couch, R. B.; Johnson, P. E.; Wilson, S. Z.; Dacso, C. C.; Bloom, K.; Quarles, J.
In: Journal of Infectious Diseases, Vol. 145, No. 4, 1982, p. 542-546.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus
AU - Greenberg, S. B.
AU - Harmon, M. W.
AU - Couch, R. B.
AU - Johnson, P. E.
AU - Wilson, S. Z.
AU - Dacso, C. C.
AU - Bloom, K.
AU - Quarles, J.
PY - 1982
Y1 - 1982
N2 - The prophylactic effect of low doses of human leukocyte interferon (HuIFN-a) against infection with rhinovirus was measured in double-blind, placebo-controlled studies with volunteer subjects. An antihistamine (chlorpheniramine) was given before administration of single or multiple doses of HuIFN-a by saturated cotton pledget or by aerosol; volunteers were then challenged with rhinovirus. When the results for all groups were combined, a lower frequency of respiratory illness was demonstrated in the HuIFNa-treated volunteers (20 of 39 vs. 11 of 38, P <0.05). A significant improvement in mean symptom scores was found only in the volunteers who received HuIFN-a by cotton pledget. The total numbers of isolates of rhinovirus and seroconversions were similar for HuIFN-a-treated and control volunteers. No significant side effects were noted in the HuIFN-a-treated volunteers. Higher concentrations or improved methods of delivery of HuIFN-a will be necessary for improving the clinical efficacy of HuIFN-a against viral infections in the respiratory system.
AB - The prophylactic effect of low doses of human leukocyte interferon (HuIFN-a) against infection with rhinovirus was measured in double-blind, placebo-controlled studies with volunteer subjects. An antihistamine (chlorpheniramine) was given before administration of single or multiple doses of HuIFN-a by saturated cotton pledget or by aerosol; volunteers were then challenged with rhinovirus. When the results for all groups were combined, a lower frequency of respiratory illness was demonstrated in the HuIFNa-treated volunteers (20 of 39 vs. 11 of 38, P <0.05). A significant improvement in mean symptom scores was found only in the volunteers who received HuIFN-a by cotton pledget. The total numbers of isolates of rhinovirus and seroconversions were similar for HuIFN-a-treated and control volunteers. No significant side effects were noted in the HuIFN-a-treated volunteers. Higher concentrations or improved methods of delivery of HuIFN-a will be necessary for improving the clinical efficacy of HuIFN-a against viral infections in the respiratory system.
UR - http://www.scopus.com/inward/record.url?scp=0020078959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020078959&partnerID=8YFLogxK
U2 - 10.1093/infdis/145.4.542
DO - 10.1093/infdis/145.4.542
M3 - Article
VL - 145
SP - 542
EP - 546
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 4
ER -